NUVL News and Press, Nuvalent Inc. From 10/30/22

Summary Two new Breakout Stocks for Week 44 with better than 10% short-term upside potential and a Dow 30 Pick. Average cumulative returns now up to +112.8% YTD. This week two stocks gained 10% in less than a week with MAG +11.5% and WTTR +10% while another high frequency breakout...

Nuvalent ( NASDAQ: NUVL ) reported initial data from the phase 1 part of a phase 1/2 trial of NVL-520 to treat patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors. As of Sept. 1, 35 people have been enrolled in the phase 1 porti...

Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC PR Newswire Favorable preliminary safety profile of NVL-520 suggests potential for a highly ROS1-selective, TRK ...

Nuvalent Announces New Preclinical Data for Selective Kinase Inhibitors NVL-330 and NVL-655 PR Newswire Preclinical data demonstrated that NVL-330 inhibits HER2 exon 20 insertion mutations, is selective for HER2 versus wild-type EGFR, and is brain-penetrant NVL...

Nuvalent to Host Conference Call to Discuss Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 and Additional Preclinical Updates in Conjunction with 34th EORTC-NCI-AACR Symposium PR Newswire CAMBRIDGE, Mass. , Oct. 17, 2022 /PRNewswire/ --...

Nuvalent Appoints Michael L. Meyers, MD, PhD, to Board of Directors PR Newswire CAMBRIDGE, Mass. , Oct. 6, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies ...

Nuvalent to Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates PR Newswire Preliminary Dose Escalation Data on ROS1-selective Inhibitor NVL-520 to be Presented in the "New Drugs on the...

Nuvalent to Participate in the Wells Fargo 2022 Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Sept. 1, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted the...

Nuvalent press release ( NASDAQ: NUVL ): Q2 GAAP EPS of -$0.38 beats by $0.03 . Cash, cash equivalents and marketable securities were $257.0 million For further details see: Nuvalent GAAP EPS of -$0.38 beats by $0.03

Nuvalent Highlights Execution Across Pipeline of Novel Kinase Inhibitors and Reports Second Quarter 2022 Financial Results PR Newswire Preliminary dose escalation data expected in second half of 2022 from the ARROS-1 study of NVL-520 for advanced ROS1 positive NSCLC an...